165 related articles for article (PubMed ID: 35951087)
21. External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer.
Boladeras A; Santorsa L; Gutierrez C; Martinez E; Pera J; Pino F; Suarez JF; Ferrer F; Díaz A; Polo A; Guedea F
Radiother Oncol; 2014 Aug; 112(2):227-32. PubMed ID: 25174299
[TBL] [Abstract][Full Text] [Related]
22. Anatomy-based inverse optimization in high-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: comparison of incidence of acute genitourinary toxicity between anatomy-based inverse optimization and geometric optimization.
Akimoto T; Katoh H; Kitamoto Y; Shirai K; Shioya M; Nakano T
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1360-6. PubMed ID: 16406395
[TBL] [Abstract][Full Text] [Related]
23. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
24. Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer.
Strouthos I; Chatzikonstantinou G; Zamboglou N; Milickovic N; Papaioannou S; Bon D; Zamboglou C; Rödel C; Baltas D; Tselis N
Radiother Oncol; 2018 Aug; 128(2):301-307. PubMed ID: 29764692
[TBL] [Abstract][Full Text] [Related]
25. High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes.
Chao M; Bolton D; Lim Joon D; Chan Y; Lawrentschuk N; Ho H; Spencer S; Wasiak J; Guerrieri M; Ow D; Troy A; Pham T; Sengupta S; Tan A; McMillan K; Koufogiannis G; Foroudi F; Ng M; Khoo V
J Med Imaging Radiat Oncol; 2019 Jun; 63(3):415-421. PubMed ID: 30908894
[TBL] [Abstract][Full Text] [Related]
26. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for urethral stricture following external beam radiotherapy and HDR brachytherapy for prostate cancer.
Groom N; Tsang Y; Lowe G; Hoskin P
Brachytherapy; 2021; 20(2):302-306. PubMed ID: 33234408
[TBL] [Abstract][Full Text] [Related]
28. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.
Kalakota K; Liauw SL
Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863
[TBL] [Abstract][Full Text] [Related]
29. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
[TBL] [Abstract][Full Text] [Related]
30. Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients.
Tanaka T; Yorozu A; Sutani S; Yagi Y; Nishiyama T; Shiraishi Y; Ohashi T; Hanada T; Saito S; Toya K; Shigematsu N
Brachytherapy; 2018; 17(5):799-807. PubMed ID: 29936128
[TBL] [Abstract][Full Text] [Related]
31. High-dose-rate brachytherapy boost for prostate cancer: Outcomes and genitourinary toxicity.
Bece A; Patanjali N; Jackson M; Whitaker M; Hruby G
Brachytherapy; 2015; 14(5):670-6. PubMed ID: 25976294
[TBL] [Abstract][Full Text] [Related]
32. Timing of High-Dose Rate Brachytherapy With External Beam Radiotherapy in Intermediate and High-Risk Localized Prostate CAncer (THEPCA) Patients and Its Effects on Toxicity and Quality of Life: Protocol of a Randomized Feasibility Trial.
Palvai S; Harrison M; Shibu Thomas S; Hayden K; Green J; Anderson O; Romero L; Lodge R; Burns P; Ahmed I
JMIR Res Protoc; 2015 Apr; 4(2):e49. PubMed ID: 25926023
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
Makino T; Mizokami A; Namiki M
Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
[TBL] [Abstract][Full Text] [Related]
34. Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy.
Tanaka N; Asakawa I; Anai S; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
Radiat Oncol; 2013 Jan; 8():25. PubMed ID: 23363647
[TBL] [Abstract][Full Text] [Related]
35. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
36. High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer.
Chin YS; Bullard J; Bryant L; Bownes P; Ostler P; Hoskin PJ
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):474-9. PubMed ID: 16909971
[TBL] [Abstract][Full Text] [Related]
37. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
[TBL] [Abstract][Full Text] [Related]
38. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
[TBL] [Abstract][Full Text] [Related]
39. HDR brachytherapy combined with external beam radiation for localised prostate cancer: early experience from the Sydney Cancer Centre.
Whalley D; Patanjali N; Jackson M; Lovett A; Chatfield M; Hruby G
J Med Imaging Radiat Oncol; 2012 Apr; 56(2):220-6. PubMed ID: 22498197
[TBL] [Abstract][Full Text] [Related]
40. Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy.
Tward JD; Jarosek S; Chu H; Thorpe C; Shrieve DC; Elliott S
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1443-1453. PubMed ID: 27325475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]